Searchable abstracts of presentations at key conferences in endocrinology

ea0090p207 | Thyroid | ECE2023

Thymic Hyperplasia and Graves’s Disease: A Non-Incidental Association

Pla Peris Begona , Abellan Galiana Pablo , Franch Salvador Sara , Gonzalez Boillos Margarita , Maravall Javier , Angel Merchante Alfaro Agustin

Introduction: Grave’s disease (GD) is an autoimmune disease characterized by the development of thyroid-stimulating hormone (TSH) receptor antibodies that have a stimulating effect on the thyroid gland. There is a rare but non-incidental and well-documented association between GD and thymic hyperplasia (TH). Nonetheless, this association is often underdiagnosed in routine clinical practice and the mechanisms behind this association have yet to be thoroughly elucidated. Th...

ea0081p417 | Pituitary and Neuroendocrinology | ECE2022

Terlipressin induced acute severe hyponatremia

Pla Peris Begona , Castro de la Vega Iciar , Roxana Padilla Segura Mayet , Serisuelo Meneu Esther , Abellan Galiana Pablo , Maravall Javier , Perez Naranjo Susana , Gonzalez Boillos Margarita , Angel Merchante Alfaro Agustin

Introduction: Terlipressin is a non-selective vasopressin analogue used in patients with decompensated cirrhosis, gastrointestinal haemorrhage or hepatorenal syndrome. It directly binds to V1 receptors improving circulatory volume by causing splanchnic vasoconstriction and portal hypertension inhibition, and has a full V2 receptor agonism in the collecting duct. In consequence, it increases reabsorption of water and can lead to a decrease in plasma osmolality and hyponatremia....